# A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)

> **NCT00632931** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 25 (actual)

## Conditions studied

- Advanced Cancer Relapsed
- Advanced Cancer Refractory

## Interventions

- **DRUG:** vorinostat
- **DRUG:** Comparator: placebo (unspecified)

## Key facts

- **NCT ID:** NCT00632931
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-05
- **Final completion:** 2009-04
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00632931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00632931, "A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00632931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*